‘Screening for ‘causes’ of hypertension – needles, haystacks & mass spec(ulation)?’

Hypertension in the blood - & urine..?

Prof Kennedy Cruickshank
Cardiovascular Medicine & Diabetes
Nutritional Sciences Division
King’s College &
King’s Health Partners (St Thomas’/Guy’s Hosps), UK
London (with Univ. West Indies, Jamaica & Barbados, Cameroon, Nigeria, Ghana & New Orleans, USA).

Variation in Flow and Pressure across the Arterial tree.. (modelled)



Note resulting Pulse Wave Velocity changes (estimated)

Courtesy of Dr A Figueroa, King's College

N. Xiao, J.D. Humphrey, C.A. Figueroa. "Multi-Scale Computational Model of Three-Dimensional Hemodynamics within a Deformable Full-Body Arterial Network." Journal of Computational Physics. DOI: 10.1016/j.jcp.**2012**.09.016

Arterial biomarker of CV events : Intermediate end-point Longitudinal study

Number of CV events



Alteration in arterial parameter

Eg:
Pulse wave velocity (PWV)
Central (aortic) BP
Augmentation ?

Age adjusted cardiovascular death rates with and without diabetes at screening for MRFIT



Vacarro et al 2003

NB: Accord Trial data 2010

Arterial Stiffness as Pulse Wave Velocity (PWV) vs SBP for all T2 Diabetes & GTTd Controls



Cruickshank et al Circulation 2002

Individual Patient Meta-analysis of Arterial Stiffness and Mortality – an **intermediary outcome** not a risk factor..

Table 1 Pooled Adjusted Hazard Ratios (95% CIs) of a 1-SD Increase in Log_e-Transformed aPWV for All-Cause Mortality, CVD Mortality, CHD Events, Stroke Events, and CVD Events

	Model 1*	Model 2*	Model 3*
CHD events (n = 1,195)	1.35 (1.22–1.50)	1.32 (1.18–1.48)	1.23 (1.11–1.35)
CVD events (n = 1,785)	1.45 (1.30–1.61)	1.37 (1.23–1.52)	1.30 (1.18–1.43)
Stroke events (n = 641)	1.54 (1.34–1.78)	1.37 (1.21–1.54)	1.28 (1.16–1.42)
CVD mortality (n = 395)	1.41 (1.27–1.56)	1.35 (1.20–1.53)	1.28 (1.15–1.43)
All-cause mortality (n = 2,041)	1.22 (1.16–1.27)	1.20 (1.15–1.26)	1.17 (1.11–1.22)

*Model 1 adjusts for sex and age group; model 2 adjusts for sex, age group, and systolic blood pressure; and model 3 additionally adjusts for other risk factors (cholesterol, high-density lipoprotein cholesterol, smoking status, presence of diabetes, and antihypertensive medication), stratified by race in the Sutton-Tyrell study (27). Not all studies had data on every risk factor.

aPWV = aortic pulse wave velocity; CHD = coronary heart disease; CI = confidence interval; CVD = cardiovascular disease.

Ben-Shlomo et al, JACC 2014

Age-adjusted blood pressure distributions of west African-origin populations



Cruickshank et al, J Hypert 2001; 19: 41-46

Barker hypothesis

- Fetal origins of Adult CVS Disease*
- Consistent, global association of poor fetal growth



- ? Nutritional inadequacy

* Barker DJP. Mothers, babies & Disease in later life. BMJ books, London 1998.

Weight Gain from Birth to 3 months & Rise in Systolic BP



Bansal et al, J Hypert 2008; 26 (3): 412-18

'Tracking' coefficients of children blood pressure: the Brompton study, UK



De Swiet et al, BMJ 1992; 304:23-26

UK: systolic BP by BMI tertiles among adolescent girls

The MRC DASH Study in London Schools



Harding, Maynard, Cruickshank, J Hypertension 2006

Cardiovascular structure and function in adult survivors of severe acute malnutrition

Ingrid A. Tennant, Debbie S. Thompson,, Alan T. Barnett, Jan Kips*, M Boyne, E Chung, A Chung, C Osmond#, MA. Hanson, PD Gluckman, P Segers*, J Kennedy Cruickshank, **Terrence E. Forrester**

Univ. West Indies Mona Jamaica

Univs. Ghent, Belgium, & Southampton, King's College London, UK

Hypertension – accepted May 2014

Differences in cardiovascular measures (SD scores) between controls vs. all SAM survivors

Measurement (standardised score)	Controls – all SAM survivors	
	Difference	95%CI, p-value
Controlled for age and sex		
Systolic blood pressure	-0.22	-0.55 to 0.12, 0.2
Diastolic blood pressure	-0.40	**-0.71 to -0.08, 0.02**
Heart rate	0.21	-0.14 to 0.56, 0.2
Pulse Wave Velocity	0.35	**0.06 to 0.65, 0.02**
Stroke Volume	0.49	**0.15 to 0.82, 0.005**
Cardiac Output	0.56	**0.23 to 0.90, 0.001**
Ejection Fraction	-0.41	**-0.76 to -0.06, 0.02**
LV outflow tract diameter	0.71	**0.39 to 1.03, <0.001**
Systemic Vascular Resistance	-0.69	**-1.03 to -0.35, <0.001**
LV Mass index	-0.02	-0.35 to 0.31, 0.9
Central Systolic BP	-0.15	-0.47 to 0.18, 0.4

Hypertension – accepted May 2014

The Impact of Malaria in Pregnancy on Changes in Blood Pressure in Children During Their First Year of Life

Omolola O. Ayoola, Olayemi O. Omotade, Isla Gemmell, Peter E. Clayton,* J. Kennedy Cruickshank*

Hypertension. 2014;63:167-172.

Table 3. Regression Analyses for Determinants of Change in Infant Blood Pressure

	ΔSBP			
Variable	β	95% CI	*P* Value	R^2
0–12 mo				
Sex (boy/girl)	−4.4	−7.72 to −1.08	0.01	
Malaria status	3.64	0.32 to 6.95	0.03	
Length SDS 0–3	−1.98	−3.56 to −0.40	0.014	
Weight SDS 0–3	…	…	…	
Weight SDS 0–12	2.41	0.98 to 3.84	0.001	0.10

Table 2. Comparison of Infant BP by Maternal Malaria With US BP Percentiles

	12 Mo (n=318)			
	Boys (n=173)			
BP Percentile	MP No (n=86)	%	MP Yes (n=87)	%
<90th	70	81.4	70	80.5
90th–94th	10	11.6	4	4.6
≥95th	6	7.0	13	14.9

BP indicates blood pressure; and MP, maternal malarial parasites detected.

X 2 Expected NB Temperature difference

Initial studies of Arterial function in Ghana

Factors related to PWV (arterial stiffness) in T2 Diabetes patients with (n=164) and without ‘High BP’ (n=83), in hypertensives (n= 78), & in similarly aged Controls (n=62)

	Standardised B	**P value**
Mean BP	**0.38**	**<0.001**
Age	**0.34**	**<0.001**
Hypertension status	**0.196**	**0.001**
BMI	**-0.172**	**0.001**
Diabetes status	**0.126**	**0.025**
WHR	0.035	0.4
Heart rate	0.035	0.4
FPG	0.016	0.8

Yeboah, Govoni, JKC, Amoah

‘Diagnosis’ of Hypertension

‘the level of BP above which treatment does more good than harm’
(Rose 1964)

= need Randomised Clinical Trials of TREATMENT to decide

Hypertension currently...

- >140/90 mmHg (30+% adults – BUT age-related)
- 98% Primary (essential)
- 2% Secondary: Adrenal gland tumours / *hyperplasia [?]*
- Kidney disease
- Renal artery stenosis
- Genetic disorders
- Drugs (OCP) Liquorice

Candidate genes screened for linkage to (high) BP in African-Americans, Caribbeans and west Africans:

- Epith. Na+ channel
- TGF- B
- Endothelin-1, Naturetic peptides
- a- receptors
- Glyc389 B1 Rc
- Aldosterone synthase
- NO synthase
- Angiotensinogen etc.

All linked, & not found on repeat sampling in other data.

cf. UK MRC's 'BRIGHT' study

Sick genes, Sick individuals or Sick populations with chronic disease? An example from studying diabetes & hypertension in African-origin populations.

Kennedy Cruickshank
with J-C Mbanya, R Wilks, B Balkau,
N McF Anderson & T Forrester

Int J Epidemiol 2001; 30: 111-117

What it's all about is

regulation of gene expression

—

not the genome itself

Primary Hyperaldosteronism

(Kaplan NM: In Kaplan's Clinical Hypertension 2002)

= Conn's syndrome

- Low Prevalence (1-2% of unselected hypertensives)

30% caused by adrenal adenoma



- **70% adrenal hyperplasia**
- V. rarely adrenal carcinoma
- glucocorticoid suppressible aldosteronism (autosomal dominant)

- Adenomata commoner in women (rare in children)

Adrenal enlargement



Fig. 2—27-year-old woman with history of Cushing's disease.
A and **B**, Axial unenhanced CT image (**A**) and coronal contrast-enhanced multiplanar reformation (**B**) show bilateral adrenal enlargement (*arrows*) and mild asymmetry of lateral limbs (*arrowheads*, **B**).

'Normal' adrenal 'limbs' <5mm

Johnson et al

Journal of the American College of Cardiology
© 2006 by the American College of Cardiology Foundation
Published by Elsevier Inc.

Vol. 48, No. 11, 2006
ISSN 0735-1097/06/$32.00
doi:10.1016/j.jacc.2006.07.059

Hypertension

A Prospective Study of the Prevalence of Primary Aldosteronism in 1,125 Hypertensive Patients

Gian Paolo Rossi, MD, FACC, FAHA, Giampaolo Bernini, MD, Chiara Caliumi, MD, Giovambattista Desideri, MD, Bruno Fabris, MD, Claudio Ferri, MD, Chiara Ganzaroli, MD, Gilberta Giacchetti, MD, Claudio Letizia, MD, Mauro Maccario, MD, Francesca Mallamaci, MD, Massimo Mannelli, MD, Mee-Jung Mattarello, MD, Angelica Moretti, MD, Gaetana Palumbo, MD, Gabriele Parenti, MD, Enzo Porteri, MD, Andrea Semplicini, MD, FAHA, Damiano Rizzoni, MD, Ermanno Rossi, MD, Marco Boscaro, MD, Achille Cesare Pessina, MD, PHD, Franco Mantero, MD, for the PAPY Study Investigators

Padova, Ancona, Reggio Emilia, Pisa, L'Aquila, Palermo, Legnano, Roma, Firenze, Torino, and Reggio Calabria, Italy

Frequency of aldosteronism in hypertension:

4.8% Aldosterone Producing Adenoma
6.4% Idiopathic Hyperaldosteronism

Primary Aldosteronism -- Mayo Clinic

No. of New Cases/yr



University of Glasgow

Algorithm for diagnosis and management of PA

Part 2-Establish subtype of PA



*Clinical features which make adenomatous Primary Aldosteronism more likely include: hypokalemia / severe hypertension / younger age /high levels of aldosterone

Morris Brown’s ‘breakthrough’

Variants of aldosterone-producing adenomas: classical Conn's may be tip of the iceberg



Brown M J Hypertension. 2014;63:24-26



Azizan E.. Brown MJ. APAs Nat Gen 2013



(**b**) Current-voltage relationship of mutants Val259Asp ($n = 9$) and Ile750Met ($n = 9$) (2 mM Ca^{2+} charge carrier).

Functional consequences of somatic mutants in Aldo-p Adenom

Azizan E.. Brown MJ. APAs Nat Gen 2

Unusual ‘pure ZG’ Adenoma



‘Searching for Adenomas…’
- Mr KA, 47y; Ghanaian-origin



Original CT



PET



Coronal - PET



Overlay

(via Morris Brown)

Le profilage des stéroïdes d'urine



Courtesy of Dr Norman Taylor

VASERA 5 10/ 1/4 + 2.5 MOTSIM washed, 03-Oct-2013 + 05:24:09





MS Tune File: kaf-311209.IPR *MS method:* steroidbaby greg.EXP

Urinary steroids & Arterial stiffness



r = 0.47,
P=0.02
N= 24

Courtesy of Dr Norman Taylor & Ms D Bobeica

Summary

- Arterial function a genuine candidate beyond high BP
- Think ‘life-course’ not just ‘adults’
- Gene variants *not* seriously implicated for the great majority of HIGH BP
- Aldosteronism.. Moving forwards..?! –

  - still not common but..

BMJ

BMJ 2012;344:d8218

Navigating the shoals in hypertension: discovery and guidance

Despite the extensive evidence underpinning treatment of high blood pressure, important questions remain. **Morris Brown**, **Kennedy Cruickshank**, and **Thomas MacDonald** argue that assumptions in recent treatment guidelines are based on insufficient evidence